Silo Pharma (SILO) announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents. “We expect that Silo’s diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy,” said Eric Weisblum, CEO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
- Silo Pharma gets European Patent Office allowance for PTSD prevention therapy
- Silo Pharma Acquires QwikAgents Platform Using Equity
- Silo Pharma Announces $1 Million Stock Repurchase Program
- Silo Pharma announces $1M share repurchase program